| Literature DB >> 32000722 |
Abstract
BACKGROUND: The evaluation of antibiotic use among hospitalized patients is a primary step required to design antibiotic stewardship intervention. There is paucity of data describing antibiotic use in hospitals across Northern Nigeria. This study evaluates the prevalence and indications for antibiotic use among inpatients in three acute care hospitals.Entities:
Keywords: Acute care hospitals; Antibiotic stewardship; Antibiotic use; Northern Nigeria; Point-prevalence; Redundant antibiotic combination
Mesh:
Substances:
Year: 2020 PMID: 32000722 PMCID: PMC6990515 DOI: 10.1186/s12879-020-4815-4
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
prevalence of antibiotic use among the specialty/ward
| Variable | Frequency | Percentage |
|---|---|---|
| Prevalence of antibiotic use | 257 | 80.1 |
| Prevalence of antibiotic based on specialty | ||
| Pediatric medical | 35 | 94.6 |
| Neonatal | 26 | 92.9 |
| Medical | 64 | 73.6 |
| Surgical | 54 | 78.3 |
| Obstetrics and gynecology | 51 | 72.9 |
| Pediatric surgical | 27 | 90.0 |
| Number of antibiotic prescription | ||
| 1 | 86 | 33.5 |
| 2 | 152 | 59.1 |
| 3 | 17 | 6.6 |
| 4 | 2 | 0.8 |
| Routes of administration | ||
| Parenteral | 250 | 55.7 |
| Oral | 199 | 44.3 |
| Indication for antibiotic prescription | ||
| Community infection | 174 | 38.7 |
| Hospital infection | 73 | 16.3 |
| Medical prophylaxis | 67 | 14.9 |
| Surgical prophylaxis | 101 | 22.5 |
| Unknown indication | 34 | 7.6 |
classes of antibiotic prescribed among hospitalized patients based on the indications
| Classes of antibiotic | Frequency (%) | |||||
|---|---|---|---|---|---|---|
| Total | CI | HI | SP | MP | UI | |
| Nitroimidazoles | 128 (28.5) | 46 (26.4) | 23 (31.5) | 34 (33.7) | 13 (19.4) | 12 (35.3) |
| Third generation cephalosporins | 85 (18.9) | 26 (14.9) | 15 (20.5) | 21 (20.8) | 16 (23.9) | 7 (20.6) |
| Fluoroquinolones | 61 (13.6) | 33 (19.0) | 8 (11.0) | 8 (7.9) | 5 (7.5) | 7 (20.6) |
| Penicillins – beta lactamase inhibitors | 47 (10.5) | 18 (10.3) | 8 (11.0) | 11 (10.9) | 7 (10.4) | 3 (8.8) |
| Aminoglycosides | 38 (8.5) | 13 (7.5) | 10 (13.7) | 4 (4.0) | 10 (14.9) | 1 (2.9) |
| Penicillins | 38 (8.5) | 11 (6.3) | 4 (5.5) | 8 (7.9) | 12 (17.9) | 3 (8.8) |
| Second generation cephalosporins | 17 (3.8) | 6 (3.4) | 2 (2.7) | 9 (8.9) | 0 (0.0) | 0 (0.0) |
| Lincosamides | 14 (3.1) | 9 (5.2) | 1 (1.4) | 3 (3.0) | 1 (1.5) | 0 (0.0) |
| Macrolides | 8 (1.8) | 6 (3.4) | 0 (0.0) | 1 (1.0) | 1 (1.5) | 0 (0.0) |
| Sulphonamides | 4 (0.9) | 2 (1.1) | 1 (1.4) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
| Tetracyclines | 4 (0.9) | 1 (0.6) | 0 (0.0) | 2 (2.0) | 0 (0.0) | 1 (2.9) |
| Amphenicols | 3 (0.7) | 3 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Carbapenems | 1 (0.2) | 0 (0.0) | 1 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Nitrofuran derivatives | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
| Proportion of broad spectrum antibiotics | 147 (32.7) | 59 (33.9) | 32 (43.8) | 42 (41.6) | 21 (31.3) | 14 (41.2) |
CI Community acquired infections, HI Hospital acquired infections, SP Surgical prophylaxis, MP Medical prophylaxis and UI Unknown indication
Antibiotics prescribed among hospitalized patients disaggregated based on ward specialty
| Antibiotic | Pediatric medical | Neonatal | Medical | Surgical | OBG | Pediatric surgical | Total |
|---|---|---|---|---|---|---|---|
| Metronidazole | 8 (13.6) | 0 (0.0) | 33 (28.9) | 25 (29.4) | 12 (13.5) | 21 (36.8) | 99 (30.5) |
| Ciprofloxacin | 3 (5.1) | 0 (0.0) | 21 (18.4) | 18 (21.2) | 7 (7.9) | 6 (10.5) | 55 (17.1) |
| Ceftriaxone | 17 (28.8) | 2 (4.4) | 18 (15.8) | 12 (14.1) | 4 (4.5) | 1 (1.8) | 54 (16.8) |
| Amoxicillin-clavulanate | 0 (0.0) | 1 (2.2) | 14 (12.3) | 13 (15.3) | 11 (12.4) | 1 (1.8) | 40 (12.5) |
| Gentamicin | 10 (16.9) | 18 (40.0) | 2 (1.8) | 0 (0.0) | 1 (1.1) | 7 (12.3) | 38 (11.8) |
| Tinidazole | 0 (0.0) | 0 (0.0) | 2 (1.8) | 3 (3.5) | 23 (25.8) | 0 (0.0) | 28 (8.7) |
| Cefixime | 2 (3.4) | 0 (0.0) | 2 (1.8) | 0 (0.0) | 18 (20.2) | 0 (0.0) | 22 (6.9) |
| Amoxicillin | 3 (5.1) | 0 (0.0) | 2 (1.8) | 0 (0.0) | 1 (1.1) | 12 (21.1) | 18 (5.6) |
| Cefuroxime | 3 (5.1) | 3 (6.7) | 1 (0.9) | 3 (3.5) | 3 (3.4) | 4 (7.0) | 17 (5.3) |
| Clindamycin | 0 (0.0) | 1 (2.2) | 4 (3.5) | 7 (8.2) | 1 (1.1) | 1 (1.8) | 14 (4.4) |
| Ampicillin-cloxacillin | 4 (6.8) | 4 (8.9) | 0 (0.0) | 1 (1.2) | 2 (2.2) | 0 (0.0) | 11 (3.4) |
| Ceftazidime | 0 (0.0) | 7 (15.6) | 2 (1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (2.8) |
| Crystalline penicillin | 4 (6.8) | 2 (4.4) | 1 (0.9) | 0 (0.0) | 0 (0.0) | 1 (1.8) | 8 (2.5) |
| Ampicillin-sulbactam | 0 (0.0) | 7 (15.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (2.2) |
| Azithromycin | 1 (1.7) | 0 (0.0) | 5 (4.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (1.9) |
| Levofloxacin | 0 (0.0) | 0 (0.0) | 2 (1.8) | 2 (2.4) | 0 (0.0) | 2 (3.5) | 6 (1.9) |
| Cotrimoxazole | 1 (1.7) | 0 (0.0) | 2 (1.8) | 0 (0.0) | 1 (1.1) | 0 (0.0) | 4 (1.2) |
| Doxycycline | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (4.5) | 0 (0.0) | 4 (1.2) |
| Chloramphenicol | 2 (3.4) | 0 (0.0) | 1 (0.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (0.9) |
| Erythromycin | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.1) | 0 (0.0) | 2 (0.6) |
| Ampicillin-floxacillin | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.3) |
| Secnidazole | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.3) |
| Meropenem | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.8) | 1 (0.3) |
| Nitrofurantoin | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.2) | 0 (0.0) | 0 (0.0) | 1 (0.3) |
OBG Obstetrics and gynecology
Distribution of antibiotics prescribed based on indications
| Antibiotic | CI | HI | SP3 | MP | UI |
|---|---|---|---|---|---|
| Ciprofloxacin | 29 (16.7) | 8 (11.0) | 7 (6.9) | 4 (6.0) | 7 (20.6) |
| Levofloxacin | 4 (2.3) | 0 (0.0) | 1 (1.0) | 1 (1.5) | 0 (0.0) |
| Ceftriaxone | 21 (12.1) | 6 (8.2) | 8 (7.9) | 13 (19.4) | 6 (17.6) |
| Cefuroxime | 6 (3.4) | 2 (2.7) | 9 (8.9) | 0 (0.0) | 0 (0.0) |
| Cefixime | 4 (2.3) | 4 (5.5) | 13 (12.9) | 0 (0.0) | 1 (2.9) |
| Ceftazidime | 1 (0.6) | 5 (6.8) | 0 (0.0) | 3 (4.5) | 0 (0.0) |
| Metronidazole | 41 (23.6) | 15 (20.5) | 21 (20.8) | 11 (16.4) | 11 (32.4) |
| Tinidazole | 5 (2.9) | 7 (9.6) | 13 (12.9) | 2 (3.0) | 1 (2.9) |
| Secnidazole | 0 (0.0) | 1 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Ampicillin-sulbactam | 2 (1.1) | 3 (4.1) | 0 (0.0) | 1 (1.5) | 1 (2.9) |
| Amoxicillin-clavulanate | 16 (9.2) | 5 (6.8) | 11 (10.9) | 6 (9.0) | 2 (5.9) |
| Amoxicillin | 6 (3.4) | 2 (2.7) | 8 (7.9) | 1 (1.5) | 1 (2.9) |
| Ampicillin-cloxacillin | 1 (0.6) | 1 (1.4) | 0 (0.0) | 8 (11.9) | 1 (2.9) |
| Ampicillin-floxacillin | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.9) |
| Crystalline penicillin | 4 (2.3) | 1 (1.4) | 0 (0.0) | 3 (4.5) | 0 (0.0) |
| Erythromycin | 1 (0.6) | 0 (0.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) |
| Azithromycin | 5 (2.9) | 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
| Cotrimoxazole | 2 (1.1) | 1 (1.4) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
| Doxycycline | 1 (0.6) | 0 (0.0) | 2 (2.0) | 0 (0.0) | 1 (2.9) |
| Chloramphenicol | 3 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Gentamicin | 13 (7.5) | 10 (13.7) | 4 (4.0) | 10 (14.9) | 1 (2.9) |
| Clindamycin | 9 (5.2) | 1 (1.4) | 3 (3.0) | 1 (1.5) | 0 (0.0) |
| Meropenem | 0 (0.0) | 1 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Nitrofurantoin | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
CI Community acquired infections, HI Hospital acquired infections, SP Surgical prophylaxis, MP Medical prophylaxis and UI Unknown indication